PEO6 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO4 Cell Line
Invented by Simon Langdon from The University of Edinburgh
Invented at Cancer Research UK Edinburgh Centre
- Datasheet
- References (18)
- Inventor Info
Info
| Catalogue Number | 151673 |
| Host | Human |
| Tissue | Ovary |
| Disease Keywords | Adenocarcinoma |
| Model | Tumour line |
| Relevance | The PEO4 cell line is one of nine from the PE ovarian adenocarcinoma panel (derived from 4 patients at varying stages of ovarian cancer, isolated from various malignant sites, and at various treatment stages) which provides a model system for research into the mechanism of oestrogen action on ovarian adenocarcinoma tumour cells, and for the study of efficacy and toxicity of oestrogen protagonists. PEO4 is an adherent cell line derived from a malignant effusion from the peritoneal ascites of a patient with a poorly differentiated serous adenocarcinoma. The patient previously received cisplatin, 5-fluorouracil and chlorambucil treatment. PEO4 was collected after clinical resistance developed to chemotherapy. PEO4 is tumourigenic in immunologically-deprived CBA mice. PEO4 exhibits good growth in semi-solid medium (agar). PEO4 is from the same patient as the PEO1 and PEO6 cell lines |
| Research Area | Cancer, Drug Discovery & Development |
| Growth/Phenotype Keywords | Adherent |
| Recommended Growing Conditions | RPMI-1640 + 2mM Glutamine + 2mM Sodium Pyruvate + 10% Foetal Bovine Serum. Split sub-confluent cultures (70-80%) 1:4 to 1:10 seeding at 2- 3 x 104 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. Doubling time approximately 37 hours. |
| Cellosaurus ID | CVCL_2690 |
PEO14 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO16 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO23 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO1-CDDP Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
Antigen/Gene or Protein Targets: Human ovarian cancer; oestrogen receptor, drug resistance, cisplatin resistance
0
reviews
2
references
1
supplier
TO14 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEA1 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEA2 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
References: 18 entries
Matassa et al. 2016. Cell Death Differ. :. PMID: 27206315.
Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.
Europe PMC ID: 27206315
The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
Europe PMC ID: 26683361
Huang et al. 2015. Oncotarget. :. PMID: 26683361.
Shields et al. 2015. Mol Syst Biol. 11(12):842. PMID: 26655797.
A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.
Europe PMC ID: 26655797
Patel et al. 2015. Cell Oncol (Dordr). :. PMID: 26266765.
Metformin and epithelial ovarian cancer therapeutics.
Europe PMC ID: 26266765
Hearn et al. 2015. Proc Natl Acad Sci U S A. :. PMID: 26162681.
Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells.
Europe PMC ID: 26162681
Tuthill et al. 2015. Oncogene. 34(16):2138-44. PMID: 24909167.
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
Europe PMC ID: 24909167
Langdon et al. 1990. Br J Cancer. 62(2):213-6. PMID: 2386737.
Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.
Europe PMC ID: 2386737
Langdon et al. 1988. Cancer Res. 48(21):6161-5. PMID: 3167862.
Langdon et al. 1988. Cancer Res. 48(21):6166-72. PMID: 3167863.
Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cell lines.
Europe PMC ID: 3167862
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Europe PMC ID: 3167863
Add a reference
References: 18 entries
Matassa et al. 2016. Cell Death Differ. :. PMID: 27206315.
Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.
The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
Huang et al. 2015. Oncotarget. :. PMID: 26683361.
Shields et al. 2015. Mol Syst Biol. 11(12):842. PMID: 26655797.
A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.
Patel et al. 2015. Cell Oncol (Dordr). :. PMID: 26266765.
Metformin and epithelial ovarian cancer therapeutics.
Hearn et al. 2015. Proc Natl Acad Sci U S A. :. PMID: 26162681.
Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells.
Tuthill et al. 2015. Oncogene. 34(16):2138-44. PMID: 24909167.
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
Langdon et al. 1990. Br J Cancer. 62(2):213-6. PMID: 2386737.
Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.
Langdon et al. 1988. Cancer Res. 48(21):6161-5. PMID: 3167862.
Langdon et al. 1988. Cancer Res. 48(21):6166-72. PMID: 3167863.
Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cell lines.
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Add a reference
